Skip to main content

Table 2 Scale reliability and structures

From: Validation of the Korean version of the European Organization for Research and Treatment of Cancer brain cancer module (EORTC QLQ-BN20) in patients with brain tumors

 

Mean (SD)

Cronbach’s alpha

Number of items

Item-own scale correlation

Item-other scale correlation

QLQ-C30

     

Functional scales

     

Physical functioning

71.16 (24.94)

.87

5

0.55–0.90

0.16–0.55

Role functioning

69.74 (31.43)

.89

2

0.93–0.94

0.25–0.69

Emotional functioning

71.51 (23.81)

.87

4

0.79–0.87

0.27–0.56

Cognitive functioning

69.82 (25.80)

.60

2

0.77–0.87

0.23–0.55

Social functioning

71.73 (30.72)

.85

2

0.90–0.94

0.28–0.50

Global quality of life

54.19 (25.18)

.88

2

0.94–0.94

0.29–0.50

Symptom scales/items

     

Fatigue

37.42 (23.04)

.77

3

0.76–0.87

0.27–0.62

Nausea and vomiting

11.67 (17.53)

.64

2

0.66–0.94

0.19–0.38

Pain

25.11 (26.93)

.81

2

0.89–0.91

0.26–0.55

Dyspnea

20.37 (26.22)

 

1

1.00

0.30-0.51

Sleep disturbance

25.08 (31.61)

 

1

1.00

0.27–0.44

Appetite Loss

16.94 (24.90)

 

1

1.00

0.21–0.42

Constipation

17.10 (25.78)

 

1

1.00

0.14–0.25

Diarrhea

12.46 (22.57)

 

1

1.00

0.12–0.20

Financial difficulty

31.38 (35.19)

 

1

1.00

0.24–0.63

QLQ-BN20 scales

     

Future uncertainty

34.38 (23.67)

.80

4

0.72–0.84

0.21–0.47

Visual disorder

27.27 (28.22)

.83

3

0.73–0.90

0.19–0.36

Motor dysfunction

29.14 (28.92)

.85

3

0.81–0.85

0.25–0.49

Communication deficit

22.41 (27.82)

.90

3

0.84–0.92

0.18–0.50

QLQ-BN20 single items

     

Headache

33.44 (31.07)

 

1

1.00

0.30–0.41

Seizure

9.84 (23.06)

 

1

1.00

0.13–0.32

Drowsiness

43.32 (28.03)

 

1

1.00

0.26–0.42

Hair loss

21.57 (31.01)

 

1

1.00

0.00–0.26

Itchy skin

16.61 (25.05)

 

1

1.00

0.16–0.26

Weakness of legs

35.42 (33.27)

 

1

1.00

0.28–0.73

Bladder control

21.39 (30.88)

 

1

1.00

0.28–0.39

  1. QLQ-C30 Quality of Life Core Questionnaire, QLQ-BN20 Quality of Life Questionnaire Brain Cancer Module.